When a promising ALS drug failed Phase 2 trials, the company shut down. The drug's original founder, Dr. Ari Azhir, still believed in the science, repurchased the asset and all its data, and ultimately uncovered its true potential, leading to a new FDA application.

GSK's choice to abandon BPC-157 was a "portfolio decision" based on business strategy, not due to safety or efficacy failures. This common pharma practice can create a vacuum for promising compounds. By shelving the project, GSK inadvertently left the door open for unregulated online communities to champion and distribute the peptide.

To successfully acquire a shelved asset from a large pharma company, you must find a high-level internal advocate—what Annette Bakker calls a "Frida." This person must believe in the project and possess the influence to navigate internal bureaucracy and champion the out-licensing effort, which is often complex and not a corporate priority.

K-36's lead drug was acquired from Novartis not because it was a failed asset, but because it became available during a strategic reorganization. This illustrates a key opportunity for biotech startups: licensing promising preclinical assets that no longer fit a large pharmaceutical company's immediate development focus.

A practical way to find potentially abandoned drug assets is to scan the public ClinicalTrials.gov database. Andrew Lo suggests identifying trials that are still listed as active but have not been updated for a significant period. This public data provides a scalable, low-cost starting point for discovering valuable candidates that pharma companies are no longer pursuing.

Roivant's early success came from identifying and building companies around promising drug assets that were deemed non-strategic by large pharmaceutical firms. This approach capitalized on undervalued IP and focused execution, pre-dating the now-common trend of pharma spin-outs.

Discontinued drugs aren't hard to identify; the real challenge is navigating the out-licensing process inside a large pharma company. Without an internal champion to drive the complex approvals for a non-priority asset, promising drugs can languish on the shelf due to corporate inertia, not a desire to hide them.

The ultimate vision is a dynamic marketplace where pharma companies routinely list their shelved assets. This "eBay for drug candidates" would allow interested parties—from biotechs to patient advocacy groups—to access information, assess opportunities, and bid on developing these assets, creating a systematic and efficient repurposing pipeline.

To maintain focus during its pivot to rare diseases, Zevra aggressively culled its portfolio of inherited and acquired assets. This involved deprioritizing programs, returning rights to originators, and divesting entire portfolios to eliminate distractions and monetize non-core intellectual property.